Levodropropizine PCD Pharma Franchise Company

Cafoli Lifecare is a trusted Levodropropizine PCD pharma franchise company offering 2 syrup formulations. Manufactured at WHO-GMP certified facilities, this range gives franchise partners a peripherally acting, non-sedating antitussive well suited to the large paediatric and adult dry-cough market.

What is Levodropropizine?

Levodropropizine is a peripherally acting non-opioid antitussive. Rather than suppressing the brain’s cough centre, it acts on the sensory nerve endings of the respiratory tract, dampening the stimulation of cough receptors and the release of neuropeptides that trigger the cough reflex. This peripheral mechanism relieves cough with minimal central sedation, making it particularly suitable for children. Learn more on PubChem.

Therapeutic Applications of Levodropropizine

Levodropropizine is used for the symptomatic treatment of dry, irritating, non-productive cough in both adults and children, including cough due to upper-respiratory infections. It is prescribed by paediatricians, general physicians and chest physicians.

Why Levodropropizine is a High-Potential Molecule for Distributors

With dry cough a constant, high-frequency complaint across all age groups in India, antitussive syrups enjoy sustained year-round demand. Levodropropizine’s peripheral, non-sedating action gives it a clear paediatric advantage over central and opioid cough suppressants, positioning it as a differentiated, physician-preferred molecule that distributors can promote strongly in child and family healthcare.

Why Choose Cafoli Lifecare

Cafoli Lifecare offers exclusive district-wise monopoly rights, WHO-GMP certified and DCGI-approved formulations, attractive promotional inputs and marketing support, and the reliability of a network trusted by 1000+ franchise partners across India.

References

1. PubChem – Levodropropizine Compound Summary, U.S. National Library of Medicine
2. PubMed – Clinical literature on Levodropropizine